09/21/23 4:22 PMNasdaq : HLTH Cue Health Adopts Limited-Duration Shareholder Rights PlanCue Health, a healthcare technology company, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration shareholder rights plan to protect the long-term interests of all shareholders. The Board adopted the Rights Plan in response to a rapid accumulation of shares by a third party. The Rights Plan is effective...RHEA-AIpositive
08/31/23 10:00 AMNasdaq : HLTH Tarsadia Investments Sends Letter to Board of Cue Health, Inc.Tarsadia Investments, LLC represents long-term stockholders of Cue Health, Inc., with holdings that collectively make them a top 10 stockholder. Today, Tarsadia sent an open letter to the board of directors of Cue highlighting the urgent need for the Board to act. Board of Directors Cue Health, Inc. 4980 Carroll Canyon Rd., Suite 100 San Diego, CA 92121.RHEA-AIneutral
08/23/23 8:00 AMNasdaq : HLTH conferencesCue Health to Present at Upcoming Investor ConferencesCue Health, a healthcare technology company, announced today that its management team will present at the following investor conferences:. 2023 Wells Fargo Healthcare Conference Presenting via fireside chat on Wednesday, September 6, 2023 at 3:00 p.m. Eastern Time in Boston, MA at the Encore Boston Harbor Morgan Stanley 21 st Annual Global Healthcare...RHEA-AIneutral
08/09/23 4:01 PMNasdaq : HLTH earningsCue Health Reports Second Quarter 2023 Financial ResultsReported second quarter total revenue of $10 million at the top-end of our guidance. Received landmark first, over-the-counter De Novo authorization from the FDA for the Cue COVID-19 Molecular Test. Awarded a new $28.3 million contract from BARDA, the U.S. Biomedical Advanced Research and Development Authority, to accelerate the development, validation, and...RHEA-AIneutral
08/03/23 4:22 PMNasdaq : HLTH covid-19Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care UseCue Health, a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to develop a Flu A/B, RSV, and COVID-19...RHEA-AIneutral
07/26/23 4:01 PMNasdaq : HLTH earningsCue Health to Announce Second Quarter 2023 Financial ResultsCue Health Inc., a healthcare technology company, announced today that it will release its second quarter 2023 financial results on Wednesday, August 9, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.RHEA-AIneutral
06/06/23 3:49 PMNasdaq : HLTH covid-19Cue Health Achieves Groundbreaking Milestone with FDA: First Company to Receive De Novo Authorization for a COVID-19 Home Use TestCue Health, a healthcare technology company, announces an industry breakthrough as the first company to receive De Novo authorization from the U.S. Food and Drug Administration for its Cue COVID-19 Molecular Test, designed for both home and point-of-care use. This sets a new standard as the first FDA De Novo authorization for a home use COVID-19 test and the...RHEA-AIneutral
05/31/23 4:01 PMNasdaq : HLTH conferencesCue Health to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceCue Health, a healthcare technology company, announced today that its management team will present at the Goldman Sachs 44 th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. Pacific Time at the Waldorf Astoria Monarch Beach Resort& Club. A live audio webcast and replay of the presentation may be accessed for 180 days on the“ Investor...RHEA-AIneutral
05/10/23 4:05 PMNasdaq : HLTH earningsCue Health Reports First Quarter 2023 Financial ResultsReported first quarter revenue of $24.8 million Granted U.S. Food and Drug Administration Emergency Use Authorization for Cue Mpox Molecular Test for point-of-care use Submitted the Cue RSV Molecular Test as a De Novo submission to the FDA for home and point-of-care use during the second quarter, as planned Launched Cue Pharmacy, a new Cue Integrated Care...RHEA-AInegative
05/09/23 9:15 AMNasdaq : HLTH clinical trialCue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® RSV Molecular TestCue Health, a healthcare technology company, today announced that it has made a De Novo submission to the U.S. Food and Drug Administration for full clearance of the Cue RSV Molecular Test for at-home and point-of-care use. There are currently no respiratory syncytial virus tests on the market for home use. It is the most common cause of bronchiolitis and...RHEA-AIneutral